|
|
|
|
The effects of treatment with ropinirole (0.25 to 0.5 mg bid) were examined using an open-label design for 8 weeks in 15 subjects with Gilles de la Tourette syndrome (GdlT). All patients completed the study and most showed an improvement in their tics during treatment. Low-dose ropinirole may improve the motor features in GdlT, but further controlled studies are necessary. |
|